Ones To Watch News
Refine Search
Pharmaceutical
Privately-held Xcovery Holdings, an oncology-focused pharma company, has announced that the US Food and Drug Administration (FDA) has approved Ensacove (ensartinib) for the treatment of patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). 19 December 2024
Biotechnology
Privately-held biotech Ottimo Pharma today announces the completion of a Series A financing round of over $140 million. 19 December 2024
Biotechnology
Safi Biotherapeutics, a specialist in stem-cell derived red blood cell products, has received Rare Pediatric Disease designation and Orphan Drug designation from the US regulator. 19 December 2024
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Biotechnology
Belgian G-protein coupled receptor (GPCR) company Confo Therapeutics today announced the appointment of Dieter Weinand as independent chairman of its board of directors, succeeding John Berriman, who is retiring from his current position. 29 August 2023
Biotechnology
US health care tech conglomerate Danaher Corp said Monday it has agreed to acquire Abcam, just two months after the UK antibody research expert launched a strategic review of the company. 29 August 2023
Biotechnology
German developer of next-generation CAR-T cell therapies for cancer patients, T-CURX GmbH, has announced the appointments of Dr Hans-Peter (HP) Gerber as chairman. 28 August 2023
Biotechnology
Shares in Apellis Pharmaceuticals soared 30.2% to close at $40.04 yesterday after it provided more information regarding the safety of its eye disease product. 24 August 2023
Biotechnology
Less than six months after raising $100 million in a Series A financing, neuromedicines company Rapport Therapeutics has added another $150 million to its coffers. 24 August 2023
Biotechnology
Swedish contract development and manufacturing organization (CDMO) NorthX Biologics has appointed Janet Hoogstraate as its new chief executive. 24 August 2023
Biotechnology
Seattle, USA-based Alpine Immune Sciences, an immunotherapy company developing innovative treatments for autoimmune and inflammatory diseases, has named Christina Yi its new chief technology officer. 24 August 2023
Pharmaceutical
Fulcrum Therapeutics saw its shares gain as much as 48.5% to $5.82 pre-market yesterday following an update from the US Food and Drug Administration (FDA). 23 August 2023
Biotechnology
California, USA-based clinical stage biotech Neuron2 has appointed Andrew Yost as the company’s chief business officer (CBO). 23 August 2023
Biotechnology
Oxford, UK-based techbio innovator Etcembly is coming out of stealth mode, kickstarting the next generation of immunotherapies with a pipeline of best-in-class T cell receptor (TCR) therapeutics designed using generative AI. 23 August 2023
Pharmaceutical
Exelixis and Ipsen have announced that the Phase III CONTACT-02 pivotal trial met one of two primary endpoints, demonstrating a statistically-significant improvement in progression-free survival (PFS) at the primary analysis. 22 August 2023
Biotechnology
California-based Genesis Therapeutics, a company seeking to use artificial intelligence (AI) to create medicines, has closed an oversubscribed $200 million round of Series B financing. 22 August 2023
Biotechnology
US mRNA specialist Moderna saw its shares close up 9.3% at $111.08 on Monday after the announcement of a collaboration agreement to investigate Shanghai, China-based CARsgen Therapeutics’ investigational Claudin18.2 CAR T-cell product candidate (CT041) in combination with Moderna’s investigational Claudin18.2 mRNA cancer vaccine. 22 August 2023
Biotechnology
US clinical-stage biotech Apogee Therapeutic has appointed Mark McKenna as chairman of its board of directors. 22 August 2023
Biotechnology
Neuroscience-focused Neurocrine Biosciences has won US Food and Drug Administration (FDA) approval for Ingrezza (valbenazine) capsules to treat adults with chorea associated with Huntington's disease (HD). 21 August 2023
Pharmaceutical
US rare and orphan dermatologic diseases firm Timber Pharmaceuticals saw it shares almost double to $2.79 this morning, on the news of a takeover bid. 21 August 2023
Pharmaceutical
UK addiction treatment specialist Indivior (LSE/Nasdaq: INDV) saw its shares edge up 3% to 1,812 pence by early afternoon, as it revealed a resolution to the claims brought by the end payor class of litigants in the In re Suboxone Antitrust Litigation multi-district litigation (MDL). 21 August 2023
Biotechnology
Flagship Pioneering company Alltrna, which is unlocking transfer RNA (tRNA) biology and pioneering tRNA therapeutics to regulate the protein universe and resolve disease, has appointed Chris Henderson, as chief scientific officer and promoted William (Will) Kiesman, to the post of chief technology officer. 19 August 2023
Biotechnology
US biotech Selecta Biosciences is to freeze investment on all pipeline assets except SEL-212, which is being developed for the treatment of chronic refractory gout. 18 August 2023
Biotechnology
Massachusetts, USA-based cell therapy specialist Abcuro has raised $155 million in a series B financing round co-led by Redmile Group and Bain Capital Life Sciences. 17 August 2023
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze